Navigation Links
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/1/2009

TUSTIN, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:25 am EDT. The conference will be held at the New York Palace Hotel in New York City.

A live webcast of the company's presentation will be available at the Investors section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for 90 days.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/conferences?id=30

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                               Media
    info@peregrineinc.com                                   Jennifer Anderson
    (800) 987-8256                                          (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
2. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
3. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
4. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
5. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
7. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
11. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... ... for blood donations in South Texas and across the nation is growing. , But according ... donations are on the decline. In fact, donations across the country are at their lowest ... in the last four years alone. , There is no substitute for blood. , “We ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a leading independent ... Aurora, Ohio, has broken ground on a new building in Holly Springs, NC. ... this new location solidifies a commitment to business in the region. The new ...
(Date:5/20/2016)... Raleigh, NC (PRWEB) , ... May 20, 2016 , ... ... cells, suggesting that it may offer a new way to treat the disease. Surviving ... read it now. , Scientists from several Korean institutions based their mesothelioma study ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and ... Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more ... discovery studies for preclinical and clinical safety programs. “We’ve seen significant demand for, ...
Breaking Biology Technology:
(Date:3/11/2016)... India , March 11, 2016 ... a new market research report "Image Recognition Market by ... Application (Marketing and Advertising), by Deployment Type (On-Premises and ... Forecast To 2022", published by MarketsandMarkets, the global market ... 2015 to USD 29.98 Billion by 2020, at a ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
Breaking Biology News(10 mins):